Skandinaviska Enskilda Banken AB publ Has $196,000 Stake in Kyverna Therapeutics, Inc. (NASDAQ:KYTX)

Skandinaviska Enskilda Banken AB publ grew its holdings in Kyverna Therapeutics, Inc. (NASDAQ:KYTX) by 55.8% during the second quarter, Holdings Channel.com reports. The firm owned 26,195 shares of the company’s stock after acquiring an additional 9,385 shares during the period. Skandinaviska Enskilda Banken AB publ’s holdings in Kyverna Therapeutics were worth $196,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in KYTX. Federated Hermes Inc. bought a new position in shares of Kyverna Therapeutics in the second quarter valued at about $120,000. Rhumbline Advisers bought a new position in shares of Kyverna Therapeutics in the second quarter worth about $150,000. DekaBank Deutsche Girozentrale bought a new position in shares of Kyverna Therapeutics in the first quarter worth about $181,000. Teachers Retirement System of The State of Kentucky acquired a new position in shares of Kyverna Therapeutics during the first quarter worth approximately $313,000. Finally, Sofinnova Investments Inc. grew its stake in shares of Kyverna Therapeutics by 378.5% during the second quarter. Sofinnova Investments Inc. now owns 47,850 shares of the company’s stock valued at $359,000 after purchasing an additional 37,850 shares during the last quarter. Institutional investors own 18.08% of the company’s stock.

Kyverna Therapeutics Stock Down 4.4 %

KYTX opened at $5.59 on Wednesday. The company has a fifty day moving average price of $7.71 and a two-hundred day moving average price of $13.19. Kyverna Therapeutics, Inc. has a 52 week low of $5.53 and a 52 week high of $35.06.

Kyverna Therapeutics (NASDAQ:KYTX) last announced its quarterly earnings data on Monday, August 12th. The company reported ($0.67) EPS for the quarter, topping analysts’ consensus estimates of ($0.70) by $0.03. As a group, research analysts predict that Kyverna Therapeutics, Inc. will post -3.38 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have issued reports on KYTX shares. JPMorgan Chase & Co. reduced their price objective on Kyverna Therapeutics from $39.00 to $33.00 and set an “overweight” rating on the stock in a report on Wednesday, July 31st. HC Wainwright reaffirmed a “neutral” rating and set a $7.00 price target on shares of Kyverna Therapeutics in a research note on Thursday, September 19th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat.com, Kyverna Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $34.40.

Kyverna Therapeutics Company Profile

Kyverna Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.